TCVGH and Boehringer Ingelheim signed an MOU to develop clinical trials for new drug research

撰文GlobalBio & Investment
日期2024-08-06
EnglishFrenchGermanItalianPortugueseRussianSpanish
Left: James Chiou, Managing Director at Boehringer Ingelheim Taiwan; Right: Dr. Chen Shih-Ann, Superintendent at TCVGH

On 6th Aug, 2024, Taichung Veterans General Hospital (TCVGH) announced that it had signed an MOU with Boehringer Ingelheim to develop smart clinical trials for new drug research in six major specialties: pulmonary, cardio-renal-metabolic diseases, oncology, schizophrenia, immunology, and ophthalmology. This collaboration aims to optimize clinical trial processes, including participant screening, consent signing, home visits, and remote physiological data collection, to maximize innovative research capabilities. 

James Chiou, Managing Director at Boehringer Ingelheim Taiwan, emphasized that their previous collaborations with TVGH have focused on early-phase clinical trials in areas such as pulmonary fibrosis, cancer, and autoimmune diseases. TVGH has achieved top rankings in trial recruitment for pulmonary fibrosis, positioning itself among the top 3% of global trial centers. 

You can find more information here: https://news.gbimonthly.com/tw/article/show.php?num=70101

​​​​​​


(Photo Credit: Boehringer Ingelheim Taiwan)